Fair 35°
Tag:

Clinical Trial

News
FDA Approves First Non-Opioid Painkiller In 20+ Years: 'A Historic Milestone' FDA Approves First Non-Opioid Painkiller In 20+ Years: 'A Historic Milestone'
FDA Approves First Non-Opioid Painkiller In 20+ Years: 'A Historic Milestone' The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain. Journavx received FDA approval, the agency announced on Thursday, Jan. 30. The drug developed by Boston-based Vertex Pharmaceuticals blocks sodium channels in the peripheral nervous system, preventing pain signals from reaching the brain. The approval marks the first new class of pain medicine in more than two decades and offers a potential non-addictive alternative to opioids. "Today's approval is a historic milestone f…

SHARE

by Chris Spiker
News
$62K Raised For NJ Mom Battling 'Cancer With No Real Cure' $62K Raised For NJ Mom Battling 'Cancer With No Real Cure'
$62K Raised For NJ Mom Battling 'Cancer With No Real Cure' Danielle Rolon was in remission for two months before her cancer came back, but worse. Rolon, a Somerville mom, was diagnosed with breast cancer triple negative breast cancer when her third child was four months old, she said on a GoFundMe page she launched for herself and her family. She underwent five months of weekly chemotherapy, a double mastectomy and 25 rounds of radiation. Then, Rolon underwent a clinical trial and her cancer went into remission but it was short- lived.  "I started to feel great and decided to get back to the gym," she writes. "After three days at the gy…

SHARE

by Sam Barron
News
Every Cancer Patient In Remission After Miraculous Memorial Sloan Kettering Drug Trial Every Cancer Patient In Remission After Miraculous Memorial Sloan Kettering Drug Trial
Every Cancer Patient In Remission After Miraculous Memorial Sloan Kettering Drug Trial More than 15 rectal cancer patients who participated in a drug trial at Memorial Sloan Kettering Cancer Center are in remission. The first patient to try the drug was Washington DC's Sascha Roth, who got the good news on a Friday evening just four weeks before she was scheduled to undergo weeks of radiation therapy. More than a dozen others would soon receive the good news. The MSK clinical trial was investigating if immunotherapy alone could beat rectal cancer that had not spread to other tissues, in a subset of patients whose tumor contained a specific genetic mutation, the hospital sai…

SHARE

by Cecilia Levine
News
NJ-Based Johnson & Johnson Pauses COVID-19 Vaccine Trial Due To Unexplained Participant Illness NJ-Based Johnson & Johnson Pauses COVID-19 Vaccine Trial Due To Unexplained Participant Illness
Nj-based Johnson & Johnson Pauses Covid-19 Vaccine Trial Due To Unexplained Participant Illness New Jersey-based Johnson & Johnson has paused its COVID-19 vaccine study because of an unexplained illness among a participant. Researchers running the 60,000 patient trial received a notice saying the "pausing rule has been met," Stat News reports. The online patient-enrolling system was subsequently closed and a meeting for the patient safety monitoring board comprised of independent committee met Monday evening, the report says. J&J -- based in New Brunswick -- declined to tell Stat News anything more than a study participant suffered an unexplained illness. The company began e…

SHARE

by Cecilia Levine